Loading…
for educational and safety purposes
ETH-LAD and 1P-ETH-LAD both come up in the same conversations; they overlap on Serotonin. ETH-LAD: ETH-LAD (6-ethyl-6-nor-lysergic acid diethylamide) is a lysergamide psychedelic and close structural analogue of LSD in which the N-6 methyl group of the ergoline scaffold is replaced by an ethyl group. 1P-ETH-LAD: 1P-ETH-LAD (1-propionyl-ETH-LAD) is a research lysergamide combining two structural modifications of LSD; the 6-position N-ethyl substitution that defines the highly potent ETH-LAD, together with a propionyl group on the indole nitrogen.
ETH-LAD (6-ethyl-6-nor-lysergic acid diethylamide) is a lysergamide psychedelic and close structural analogue of LSD in which the N-6 methyl group of the ergoline scaffold is replaced by an ethyl group. Like LSD and other serotonergic hallucinogens it acts as an agonist at the 5-HT2A receptor, the principal molecular target mediating classical psychedelic effects, and lysergamides in this series reliably induce the 5-HT2A-dependent head-twitch response in rodents. It emerged as a research chemical distributed on blotters and in powders, alongside its 1-acyl prodrug 1P-ETH-LAD, which hydrolyses to ETH-LAD in serum. Users and comparative surveys describe effects broadly similar in time course to LSD but often report greater potency, more pronounced visual activity, and a heavier or more anxiogenic body load, and its analytical and metabolic profiles have been characterised to support forensic detection.
1P-ETH-LAD (1-propionyl-ETH-LAD) is a research lysergamide combining two structural modifications of LSD; the 6-position N-ethyl substitution that defines the highly potent ETH-LAD, together with a propionyl group on the indole nitrogen. Incubation with human serum demonstrates progressive hydrolysis of 1P-ETH-LAD to ETH-LAD, consistent with prodrug behavior analogous to other N1-acyl lysergamides. ETH-LAD itself is a potent 5-HT2A receptor agonist, so the compound is expected to yield a strong, markedly visual LSD-like psychedelic experience. In vitro metabolic studies place it among a family of LSD-based new psychoactive substances whose N-dealkylation and hydroxylation pathways are catalyzed chiefly by CYP1A2 and CYP3A4.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
agonist
agonist (via ETH-LAD)
agonist
agonist
agonist
agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.